SmithKline Relafen Patent Ruling Clears Way For Trial In 2001
Executive Summary
Patent infringement litigation between SmithKline Beecham and generic companies seeking to launch versions of Relafen (nabumetone) will likely go to trial in the first half of 2001, the company said following an Aug. 16 summary judgment ruling.
You may also be interested in...
Claritin Carcinogenicity Data Central To Protracted Review - GAO
FDA revisited Claritin animal carcinogenicity data and its relevance to humans two and a half years into its review of the Schering-Plough antihistamine following an agency restructuring, the General Accounting Office said in an Aug. 10 report.
SmithKline Beecham Relafen Patent Infringement Trial Set For October
Patent infringement litigation between SmithKline Beecham and three generic companies seeking approval for versions of Relafen (nabumetone) is scheduled to begin in October.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011